This interview with a US-based key opinion leader (KOL) provides insights into the evolving disease landscape for type 1 diabetes. The discussion includes the prescribing of basal and bolus insulins, the use of insulin pumps and continuous glucose monitoring, the potential role of adjunctive therapies, including SGLT-2 inhibitors and GLP-1 receptor agonists, and the emergence of novel therapeutics, including Sanofi’s Tzield (teplizumab), Celltrans’ Lantidra (donislecel) and Vertex Pharmaceuticals’ zimislecel.

This interview was conducted on February 17, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.